Literature DB >> 6536811

The determination of trimazosin and its metabolite CP23445 in whole blood by high performance liquid chromatography using fluorescence detection.

M A Hughes, P A Meredith, H L Elliott.   

Abstract

A sensitive and specific assay for trimazosin and its metabolite CP23445 is described. The method employs reverse-phase high performance liquid chromatography (HPLC) with fluorescence detection. The limit of detection of the assay is 1 ng/ml whole blood for trimazosin and 0.5 ng/ml for CP23445. The coefficient of variation for trimazosin and CP23445 over a typical calibration size is 5.4% and 4.9%, respectively. Various drugs that may be coadministered with trimazosin are shown not to interfere in the assay. The method has been extensively employed to study the pharmacokinetics of trimazosin and CP23445, both in man and in animals.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6536811     DOI： 10.1016/0160-5402(84)90003-2

Source DB:  PubMed          Journal:  J Pharmacol Methods        ISSN： 0160-5402


  4 in total

1.  Racial differences in drug responses--a comparative study of trimazosin and alpha 1-adrenoceptor responses in normotensive Caucasians and West Africans.

Authors:  J Vincent; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

2.  Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite.

Authors:  P A Meredith; A W Kelman; H L Elliott; J L Reid
Journal:  J Pharmacokinet Biopharm       Date:  1983-08

3.  The effect of cimetidine on the pharmacokinetics, pharmacodynamics and alpha 1-adrenoceptor responsiveness of trimazosin in man.

Authors:  J Vincent; H L Elliott; P A Meredith; D M Hughes; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Pharmacokinetics of trimazosin and its effects on blood pressure, renal function and proteinuria during short-term therapy of patients with impaired renal function and hypertension.

Authors:  C K van Kalken; J van der Meulen; P L Oe; R Vriesendorp; A J Donker
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.